---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-003646"
form_type: "8-K"
ticker: "CRVO"
cik: "0001053691"
company_name: "CervoMed Inc."
filed_at: "2023-02-16T23:59:59+00:00"
generated_at: "2026-06-19T08:37:24.241824+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Diffusion cuts nearly half of staff, pauses lead drug study; CMO departs

## Summary
- Reduction in force affecting 6 of 13 employees (~46% cut) as cash preservation measure.
- Company pauses Phase 2 study of TSC in newly diagnosed GBM; evaluating sale or out-license of TSC.
- Expects $1.1M one-time charge in Q1 2023 for termination benefits.
- Chief Medical Officer Dr. Christopher Galloway departs effective March 1, 2023; separation includes 9 months salary, pro-rated bonus.

## SEC filing metadata
- accession: 0001437749-23-003646
- form_type: 8-K
- ticker: CRVO
- cik: 0001053691
- company_name: CervoMed Inc.
- filed_at: 2023-02-16T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.02, 2.05, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1053691/000143774923003646/0001437749-23-003646-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1053691/000143774923003646/dffn20230216_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-003646
- JSON: https://secwatch.observer/filing/0001437749-23-003646.json
- Plain text: https://secwatch.observer/filing/0001437749-23-003646.txt

## Key facts
- Executive change
  Christopher D. Galloway departed as Chief Medical Officer at CervoMed Inc..
  - Action: departed
  - Role: Chief Medical Officer
  source text: As part of the reduction in force, the Company determined that Dr. Christopher D. Galloway, M.D., the Company’s Chief Medical Officer, will depart Diffusion effective March 1, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1053691/000143774923003646/0001437749-23-003646-index.htm
- Restructurings & Charges
  CervoMed Inc. announced a restructuring with charges of approximately $1.1 million affecting clinical operations function (six of the Company’s 13 current employees).
  - Type: restructuring
  - Charge: approximately $1.1 million
  - Affected area: clinical operations function
  - Headcount: six of the Company’s 13 current employees
  source text: Diffusion expects to record a one-time charge of approximately $1.1 million in the first quarter of 2023 in connection with the reduction in force, primarily related to one-time termination benefits to be paid in cash, which is expected to be completed in March 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1053691/000143774923003646/0001437749-23-003646-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.